An indication of Xtandi has been evaluated within the FINOSE collaboration
TLV has together with the agencies in Finland and Norway within FINOSE, written a joint assessment report for Xtandi at the indication “treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer”.
FINOSE is a collaboration between the HTA agencies Fimea (Finland), Norwegian Medicines Agency (Norway) and TLV (Sweden). The co-operation consists in the three agencies writing joint assessment reports for pharmaceutical products, that contain both relative clinical and health economic assessments. This is the first joint assessment report within the FINOSE collaboration.